Physician profile
Eric Yap
NPI 1639254279
$10,421.11
in general payments reported to CMS, 2019-2025
41 companies · $2,359 in 2025
The $2,359 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $853 · 2020: $219 · 2021: $509 · 2022: $1,585 · 2023: $2,279 · 2024: $2,616 · 2025: $2,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,254.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,924.68 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $1,141.68 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $907.50 | 2019-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $609.09 | 2019-2024 | |
| Pfizer INC. | $591.41 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $486.67 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Novo Nordisk INC | $325.47 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Regeneron Healthcare Solutions, INC. | $314.76 | 2022-2025 | Dupixent |
| Celgene Corporation | $285.57 | 2022-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $248.78 | 2024-2025 | Vowst, Zenpep |
| Ipsen Biopharmaceuticals, INC | $216.05 | 2024-2025 | Iqirvo, Bylvay |
| Organon LLC | $194.63 | 2022-2024 | Renflexis, Hadlima |
| Phathom Pharmaceuticals, INC. | $170.24 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $164.37 | 2020-2024 | |
| Qol Medical, LLC | $159.35 | 2021-2023 | Sucraid |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $152.94 | 2025 | Rezdiffra |
| Cook Medical LLC | $131.98 | 2021-2025 | Hemospray |
| Amgen INC. | $127.15 | 2021-2023 | Avsola, Amjevita |
| Merck Sharp & Dohme LLC | $126.82 | 2019-2024 | Dificid, Prevymis |
| Genzyme Corporation | $126.37 | 2023-2025 | |
| Davol INC. | $125.52 | 2022 | |
| Lilly USA, LLC | $123.83 | 2023-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $109.15 | 2022-2025 | Ocaliva |
| Ardelyx, INC. | $108.53 | 2022-2023 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $83.01 | 2021-2022 | |
| Daiichi Sankyo INC. | $71.17 | 2019-2024 | Injectafer |
| Allergan, INC. | $64.00 | 2019 | |
| Medtronic, INC. | $46.09 | 2022-2023 | Gi Genius |
| Ferring Pharmaceuticals INC. | $42.60 | 2019-2021 | |
| Alfasigma USA, INC. | $32.43 | 2020 | |
| Ucb, INC. | $27.72 | 2020 | |
| Recordati_rare_diseases_inc. | $25.01 | 2025 | Panhematin |
| Orphalan INC | $24.94 | 2025 | Cuvrior |
| Alnylam Pharmaceuticals INC. | $23.56 | 2025 | Oxlumo |
| Braintree Laboratories, INC. | $23.07 | 2019 | |
| Shire North American Group INC | $21.28 | 2019 | |
| Tersera Therapeutics LLC | $19.42 | 2021 | |
| Shield Therapeutics INC | $18.28 | 2024 | |
| Mallinckrodt Hospital Products INC. | $13.86 | 2023 | Terlivaz |
| Digestive Care, INC. | $12.13 | 2025 | Pertzye |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,800.65 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Yap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.